NFKB1 and neoplasm: There are various kinds of proteasome inhibitors which can be classified by different structures and reaction mechanisms (12), such as bortezomib (PS-341), carfilzomib (CFZ), NPI0052, MLN-9807 and CEP-18770, it is encouraging that all these proteasome inhibitors block activation of NF-κB that is one of the most important mechanisms for killing transformed tumor cells and is the foundation of rational combination therapy (13).